Circovirus sequences associated with piglet weight loss disease (PWD)

• US 7,407,803 B2
• Filed: 07/17/2006
• Issued: 08/05/2008
• Est. Priority Date: 12/05/1997
• Status: Expired due to Fees

• Current Assignee: Zoetis Services LLC (Zoetis Incorporated)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Hutet, Evelyne, Blanchard, Philippe, Cariolet, Roland, Mahe, Dominique, Arnauld, Claire, Le Cann, Pierre, Truong, Catherine, Jestin, André, Albina, Emmanuel, Madec, Francois
• Primary Examiner(s): SALIMI, ALI REZA
• Application Number:
  US11/487,589
• Publication Number:
  US 20070253971A1
• Time in Patent Office: 750 Days
• Field of Search: 435/320.1, 435/91.1, 435/91.33
• US Class Current: 435/320.1
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 2039/525 Virus
• CPC Class Codes: A61K 2039/5252 inactivated (killed)
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55 characterised by the host/recipient, e.g. newborn with maternal antibodies
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 2039/55522 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/58 raising an immune response against a target which is not the antigen used for immunisation
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: C07K 14/005 : from viruses
• CPC Class Codes: C07K 2319/55 : containing a fusion with a toxin, e.g. diphteria toxin
• CPC Class Codes: C12N 2710/14143 : viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/10021 : Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2750/10022 : New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2750/10034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2750/10051 : Methods of production or purification of viral material
• CPC Class Codes: C12N 2750/10061 : Methods of inactivation or attenuation
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: G01N 2333/01 : DNA viruses
• CPC Class Codes: G01N 2469/20 : Detection of antibodies in sample from host which are directed against antigens from microorganisms
• CPC Class Codes: G01N 33/56983 : Viruses
• CPC Class Codes: Y10T 428/13 : Hollow or container type article [e.g., tube, vase, etc.]

Abstract

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-strucutral polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Claims

1. An immunogenic composition comprising (a) a vector that contains and expresses a sequence having at least 90% sequence identity to SEQ ID NO:

25, (b) a porcine circovirus type B (PCVB) antigen or epitope thereof, and (c) a pharmaceutically acceptable vehicle or veterinary vehicle.

2. The immunogenic composition of claim 1, wherein the vector is a viral vector.

3. The immunogenic composition of claim 1, wherein the vector is a plasmid.

4. The immunogenic composition of claim 1, wherein the composition induces an immune response in a porcine host against type B porcine circovirus.

5. The immunogenic composition according to claim 1, further comprising at least one additional antigen and/or at least one nucleic acid selected from nucleic acids capable of expressing at least one additional antigen.

6. The immunogenic composition according to claim 1, further comprising at least one antigen selected from viral antigens and bacterial antigens and/or at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one member selected from viruses and bacteria.

7. The immunogenic composition according to claim 1, further comprising at least one member selected from viral toxins, bacterial toxins, viral antigens, and bacterial antigens and/or at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one toxin selected from viral toxins, bacterial toxins, viruses, and bacteria.

8. The immunogenic composition according to claim 7, wherein the antigen of the at least one bacteria is E. coli.

9. The immunogenic composition according to claim 1, further comprising at least one vector comprising at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one toxin selected from viral toxins, bacterial toxins, viruses, and bacteria.

10. The immunogenic composition according to claim 9, wherein the at least one vector is contained by E. coli.

11. The immunogenic composition according to claim 1, further comprising an adjuvant.

12. A method for inducing an immunological response against a porcine circovirus comprising administering to a porcine the immunogenic composition of claim 1.

13. An immunogenic composition according to claim 1, wherein the vector is capable of inducing an immunogenic reaction in a porcine host against a type B porcine circovirus.

14. The immunogenic composition of claim 2, wherein the vector is a baculovirus vector.

15. The immunogenic composition of claim 1, wherein the PCVB antigen is encoded by a sequence with at least 90% sequence identity to ORF 2 (SEQ ID NO:

25).

16. The immunogenic composition of claim 1, wherein the PCVB antigen is encoded by a sequence with at least 95% sequence identity to ORF 2 (SEQ ID NO:

25).

17. An immunogenic composition comprising (a) a vector that contains and expresses a sequence having at least 95% sequence identity to SEQ ID NO:

25, (b) a porcine circovirus type B (PCVB) antigen or epitope thereof, and (c) a pharmaceutically acceptable vehicle or veterinary vehicle.

18. The immunogenic composition of claim 17, wherein the vector is a viral vector.

19. The immunogenic composition of claim 18, wherein the viral vector is a baculovirus vector.

20. The immunogenic composition of claim 17, wherein the vector is a plasmid.

21. The immunogenic composition of claim 17, wherein the composition induces an immune response in a porcine host against type B porcine circovirus.

22. The immunogenic composition according to claim 17, further comprising at least one additional antigen and/or at least one nucleic acid selected from nucleic acids capable of expressing at least one additional antigen.

23. The immunogenic composition according to claim 17, further comprising at least one antigen selected from viral antigens and bacterial antigens and/or at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one member selected from viruses and bacteria.

24. The immunogenic composition according to claim 17, further comprising at least one member selected from viral toxins, bacterial toxins, viral antigens, and bacterial antigens and/or at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one toxin selected from viral toxins, bacterial toxins, viruses, and bacteria.

25. The immunogenic composition according to claim 24, wherein the antigen of the at least one bacteria is E. coli.

26. The immunogenic composition according to claim 17, further comprising at least one vector comprising at least one nucleic acid selected from nucleic acids capable of expressing an antigen of at least one toxin selected from viral toxins, bacterial toxins, viruses, and bacteria.

27. The immunogenic composition according to claim 26, wherein the at least one vector is contained by E. coli.

28. The immunogenic composition according to claim 17, further comprising an adjuvant.

29. A method for inducing an immunological response against a porcine circovirus comprising administering to a porcine the immunogenic composition of claim 17.

30. An immunogenic composition according to claim 17, wherein the vector is capable of inducing an immunogenic reaction in a porcine host against a type B porcine circovirus.

31. The immunogenic composition of claim 17, wherein the PCVB antigen is encoded by a sequence with at least 90% sequence identity to ORF 2 (SEQ ID NO:

25).

32. The immunogenic composition of claim 17, wherein the PCVB antigen is encoded by a sequence with at least 95% sequence identity to ORE 2 (SEQ ID NO:

25).